Buddy Lyons
Value, long/short equity, contrarian, research analyst

Hospira: Regulatory Woes, Pipeline, And Potential Takeout Offer Asymmetric Multi-Bagger Opportunity

Hospira (NYSE:HSP) is a provider of specialty injectable pharmaceuticals and infusion technologies. Despite its regulatory troubles of the past five years, Hospira is strategically one of the best positioned companies in the biopharma industry. The company's unique generic injectable capacity and its ability to develop biosimilars, both play into healthcare cost reductions around the world. We believe we are near the tail end of Hospira's regulatory woes and the stock will have a multi-year run, doubling in the next two years. The company is likely to see additional gains through several product launches over the next five years creating strong cash flows, providing opportunities to augment its pipeline and make investments in overseas manufacturing to boost margins above...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details